Loading...
XHKG
8225
Market cap12mUSD
Jul 06, Last price  
0.10HKD
1D
0.00%
Jan 2017
-52.26%
IPO
-64.50%
Name

China Health Group Inc

Chart & Performance

D1W1MN
XHKG:8225 chart
P/E
—
P/S
2.93
EPS
—
Div Yield, %
—
Shrs. gr., 5y
-0.04%
Rev. gr., 5y
-19.65%
Revenues
28m
+5.18%
57,052,00038,729,00039,186,00047,308,00037,687,00018,099,00028,688,00014,931,0005,956,00020,497,00020,241,00058,491,00059,606,00063,216,00083,063,00083,601,00013,090,00021,425,00026,454,00027,824,731
Net income
-15m
L+0.38%
15,563,0001,597,000-16,354,0006,276,000-56,928,000-153,796,0003,118,000-31,028,00044,117,000-3,353,0002,127,00030,454,00023,164,00027,792,00060,650,00036,325,000-15,843,000-58,014,000-14,519,000-14,574,766
CFO
9m
-12.19%
-1,836,000-22,623,000-30,653,0006,231,000-714,0006,716,000-6,617,000-1,779,00011,0003,390,000-6,893,00014,394,0002,858,000-485,00019,114,000-10,277,000-5,156,0001,121,00010,284,0009,030,081
Dividend
Apr 07, 20040.005 HKD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

China Health Group Inc., an investment holding company, researches and develops drugs, bio drugs, natural drugs, and synthetic drugs in the People’s Republic of China. The company offers contracted pharmaceutical development and clinical research, and post market; and post launch market research, medical science, and medical market services. It also provides hospital management, clinical research and promotion, rehabilitation tourism, and specialty hospital services, as well as Wanquan cloud health services. In addition, the company offers pharmacodynamics and clinical research of drugs. China Health Group Inc. was formerly known as Venturepharm Laboratories Limited and changed its name to China Health Group Inc. in January 2015. The company was founded in 1998 and is headquartered in Beijing, China.
URL
http://www.chgi.net
IPO date
Jul 10, 2003
Employees
40
Domiciled in
CN
Incorporated in
KY

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT